XTMAB-22

N/A

Report date: 2025/05/15 20:00:08

Base Information

Drug NameXTMAB-22

Drug Alias NameDenosumab biosimilar (Xentria )MAB-22XTMAB-22

ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human

Mechanisms of ActionUpdating

TargetsUpdating

Therapy Area/IndicationsOsteoporosis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryNetherlandsHungary

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesXentria Inc

China Registration ClassN/A

Active CompaniesXentria Inc

Inactive CompaniesN/A

Active IndicationsN/A

Inactive IndicationsOsteoporosis

ATC CodeN/A